Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2025-12-25 @ 1:44 AM
NCT ID:
NCT03956394
Eligibility Criteria:
Inclusion Criteria:
* Takayasu disease diagnosed according to the American College of Rheumatology 1990 criteria
Exclusion Criteria:
* Carotid damaged not related to Takayasu disease: atherosclerosis, post-radiation stenosis.
* Contraindication with the use of SonoVue®:
* Unstable ischemic heart disease (recent myocardial infarction, resting angina within 7 days)
* Acute heart failure
* Stage III or IV heart failure
* Severe rhythm disorders
* Patients with right-left shunt
* Severe pulmonary arterial hypertension (pulmonary arterial pressure\> 90 mmHg)
* Uncontrolled systemic hypertension
* Patients with respiratory distress syndrome
* Severe chronic obstructive pulmonary disease.
* Acute endocarditis
* Heart valve prostheses
* Sepsis
* Hypercoagulation and / or recent thromboembolic events
* Terminal stage of kidney or liver disease.
* Hypersensitivity to sulfur hexafluoride or any of the other ingredients of SonoVue®
* Pregnancy or breastfeeding.
* Participation in another biomedical research protocol.
* Refusal or incapacitation of language or psychic to sign informed consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03956394
Study Brief:
Protocol Section:
NCT03956394